Chemicals - Specialty
Build Your Comparison
Side-by-side financial analysisStock Comparison
NGVT vs FUL vs IOSP vs KWR vs CBT
Revenue, margins, valuation, and 5-year total return — side by side.
Chemicals - Specialty
Chemicals - Specialty
Chemicals - Specialty
Chemicals - Specialty
NGVT vs FUL vs IOSP vs KWR vs CBT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Chemicals - Specialty | Chemicals - Specialty | Chemicals - Specialty | Chemicals - Specialty | Chemicals - Specialty |
| Market Cap | $2.54B | $3.45B | $2.13B | $2.50B | $4.58B |
| Revenue (TTM) | $1.21B | $3.47B | $1.79B | $1.93B | $3.58B |
| Net Income (TTM) | $-128M | $152M | $114M | $4M | $285M |
| Gross Margin | 39.3% | 31.5% | 27.4% | 34.4% | 24.8% |
| Operating Margin | 22.8% | 10.9% | 8.1% | 3.7% | 15.7% |
| Forward P/E | 14.6x | 13.5x | 17.9x | 20.6x | 13.9x |
| Total Debt | $1.24B | $2.02B | $90M | $929M | $1.22B |
| Cash & Equiv. | $78M | $107M | $293M | $180M | $258M |
NGVT vs FUL vs IOSP vs KWR vs CBT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| Ingevity Corporation (NGVT) | 100 | 136.9 | +36.9% |
| H.B. Fuller Company (FUL) | 100 | 142.7 | +42.7% |
| Innospec Inc. (IOSP) | 100 | 112.1 | +12.1% |
| Quaker Chemical Cor… (KWR) | 100 | 77.8 | -22.2% |
| Cabot Corporation (CBT) | 100 | 236.6 | +136.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NGVT vs FUL vs IOSP vs KWR vs CBT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
NGVT is the #2 pick in this set and the best alternative if momentum is your priority.
- +66.6% vs IOSP's +1.4%
FUL ranks third and is worth considering specifically for value.
- Lower P/E (13.5x vs 13.9x)
IOSP is the clearest fit if your priority is sleep-well-at-night and valuation efficiency.
- Lower volatility, beta 0.70, Low D/E 6.7%, current ratio 2.79x
- PEG 0.56 vs FUL's 4.34
- Beta 0.70, yield 2.0%, current ratio 2.79x
- Beta 0.70 vs KWR's 1.36, lower leverage
KWR is the clearest fit if your priority is growth exposure.
- Rev growth 2.7%, EPS growth -102.2%, 3Y rev CAGR -1.0%
- 2.7% revenue growth vs NGVT's -17.0%
CBT carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 14 yrs, beta 0.82, yield 2.0%
- 119.6% 10Y total return vs NGVT's 111.0%
- 8.0% margin vs NGVT's -10.6%
- 2.0% yield, 14-year raise streak, vs FUL's 1.4%, (1 stock pays no dividend)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 2.7% revenue growth vs NGVT's -17.0% | |
| Value | Lower P/E (13.5x vs 13.9x) | |
| Quality / Margins | 8.0% margin vs NGVT's -10.6% | |
| Stability / Safety | Beta 0.70 vs KWR's 1.36, lower leverage | |
| Dividends | 2.0% yield, 14-year raise streak, vs FUL's 1.4%, (1 stock pays no dividend) | |
| Momentum (1Y) | +66.6% vs IOSP's +1.4% | |
| Efficiency (ROA) | 7.4% ROA vs NGVT's -7.3%, ROIC 17.4% vs 14.2% |
NGVT vs FUL vs IOSP vs KWR vs CBT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
NGVT vs FUL vs IOSP vs KWR vs CBT — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
NGVT leads in 1 of 6 categories
CBT leads 1 • FUL leads 0 • IOSP leads 0 • KWR leads 0 • 4 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
NGVT leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CBT is the larger business by revenue, generating $3.6B annually — 3.0x NGVT's $1.2B. CBT is the more profitable business, keeping 8.0% of every revenue dollar as net income compared to NGVT's -10.6%. On growth, KWR holds the edge at +8.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.2B | $3.5B | $1.8B | $1.9B | $3.6B |
| EBITDAEarnings before interest/tax | $378M | $472M | $187M | $143M | $731M |
| Net IncomeAfter-tax profit | -$128M | $152M | $114M | $4M | $285M |
| Free Cash FlowCash after capex | $246M | $121M | $77M | $143M | $459M |
| Gross MarginGross profit ÷ Revenue | +39.3% | +31.5% | +27.4% | +34.4% | +24.8% |
| Operating MarginEBIT ÷ Revenue | +22.8% | +10.9% | +8.1% | +3.7% | +15.7% |
| Net MarginNet income ÷ Revenue | -10.6% | +4.4% | +6.4% | +0.2% | +8.0% |
| FCF MarginFCF ÷ Revenue | +20.3% | +3.5% | +4.3% | +7.4% | +12.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -9.2% | -3.1% | +2.8% | +8.5% | -3.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +196.4% | +122.2% | -6.9% | +54.8% | -23.1% |
Valuation Metrics
Evenly matched — FUL and IOSP each lead in 2 of 7 comparable metrics.
Valuation Metrics
At 14.6x trailing earnings, CBT trades at a 37% valuation discount to FUL's 23.1x P/E. Adjusting for growth (PEG ratio), IOSP offers better value at 0.58x vs FUL's 7.45x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $2.5B | $3.4B | $2.1B | $2.5B | $4.6B |
| Enterprise ValueMkt cap + debt − cash | $3.7B | $5.4B | $1.9B | $3.3B | $5.5B |
| Trailing P/EPrice ÷ TTM EPS | -15.61x | 23.14x | 18.54x | -1031.86x | 14.56x |
| Forward P/EPrice ÷ next-FY EPS est. | 14.60x | 13.48x | 17.93x | 20.59x | 13.88x |
| PEG RatioP/E ÷ EPS growth rate | — | 7.45x | 0.58x | — | — |
| EV / EBITDAEnterprise value multiple | 10.05x | 9.28x | 9.39x | 12.03x | 7.14x |
| Price / SalesMarket cap ÷ Revenue | 2.17x | 0.99x | 1.20x | 1.33x | 1.23x |
| Price / BookPrice ÷ Book value/share | 87.73x | 1.76x | 1.62x | 1.83x | 2.79x |
| Price / FCFMarket cap ÷ FCF | 9.27x | 28.44x | 24.24x | 31.07x | 11.71x |
Profitability & Efficiency
CBT leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
CBT delivers a 16.8% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-156 for NGVT. IOSP carries lower financial leverage with a 0.07x debt-to-equity ratio, signaling a more conservative balance sheet compared to NGVT's 41.84x. On the Piotroski fundamental quality scale (0–9), FUL scores 7/9 vs KWR's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -156.1% | +7.6% | +8.6% | +0.3% | +16.8% |
| ROA (TTM)Return on assets | -7.3% | +2.9% | +6.3% | +0.2% | +7.4% |
| ROICReturn on invested capital | +14.2% | +7.8% | +11.2% | +6.6% | +17.4% |
| ROCEReturn on capital employed | +17.1% | +9.2% | +11.0% | +7.6% | +21.3% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 7 | 6 | 4 | 6 |
| Debt / EquityFinancial leverage | 41.84x | 1.01x | 0.07x | 0.67x | 0.71x |
| Net DebtTotal debt minus cash | $1.2B | $1.9B | -$203M | $749M | $957M |
| Cash & Equiv.Liquid assets | $78M | $107M | $293M | $180M | $258M |
| Total DebtShort + long-term debt | $1.2B | $2.0B | $90M | $929M | $1.2B |
| Interest CoverageEBIT ÷ Interest expense | -0.86x | 2.62x | — | 1.41x | 14.72x |
Total Returns (Dividends Reinvested)
Evenly matched — NGVT and CBT each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CBT five years ago would be worth $15,582 today (with dividends reinvested), compared to $6,392 for KWR. Over the past 12 months, NGVT leads with a +66.6% total return vs IOSP's +1.4%. The 3-year compound annual growth rate (CAGR) favors NGVT at 10.1% vs KWR's -9.2% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +19.8% | +6.2% | +14.7% | +4.7% | +32.1% |
| 1-Year ReturnPast 12 months | +66.6% | +15.2% | +1.4% | +22.7% | +17.4% |
| 3-Year ReturnCumulative with dividends | +33.4% | +1.5% | -7.8% | -25.1% | +26.6% |
| 5-Year ReturnCumulative with dividends | -10.8% | -0.1% | -4.2% | -36.1% | +55.8% |
| 10-Year ReturnCumulative with dividends | +111.0% | +50.6% | +105.2% | +77.9% | +119.6% |
| CAGR (3Y)Annualised 3-year return | +10.1% | +0.5% | -2.7% | -9.2% | +8.2% |
Risk & Volatility
Evenly matched — IOSP and CBT each lead in 1 of 2 comparable metrics.
Risk & Volatility
IOSP is the less volatile stock with a 0.70 beta — it tends to amplify market swings less than KWR's 1.36 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CBT currently trades 98.0% from its 52-week high vs KWR's 78.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.27x | 1.18x | 0.70x | 1.36x | 0.82x |
| 52-Week HighHighest price in past year | $79.05 | $68.63 | $92.14 | $183.00 | $89.46 |
| 52-Week LowLowest price in past year | $39.74 | $48.71 | $65.58 | $111.32 | $58.33 |
| % of 52W HighCurrent price vs 52-week peak | +91.1% | +92.7% | +94.0% | +78.9% | +98.0% |
| RSI (14)Momentum oscillator 0–100 | 55.7 | 58.2 | 71.7 | 53.5 | 57.0 |
| Avg Volume (50D)Average daily shares traded | 211K | 483K | 176K | 151K | 382K |
Analyst Outlook
Evenly matched — FUL and CBT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: NGVT as "Buy", FUL as "Buy", IOSP as "Hold", KWR as "Buy", CBT as "Buy". Consensus price targets imply 32.8% upside for IOSP (target: $115) vs -1.9% for CBT (target: $86). For income investors, CBT offers the higher dividend yield at 2.02% vs KWR's 1.36%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $76.67 | $68.25 | $115.00 | $176.75 | $86.00 |
| # AnalystsCovering analysts | 13 | 15 | 9 | 14 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | +1.4% | +2.0% | +1.4% | +2.0% |
| Dividend StreakConsecutive years of raises | — | 38 | 12 | 18 | 14 |
| Dividend / ShareAnnual DPS | — | $0.91 | $1.70 | $1.97 | $1.77 |
| Buyback YieldShare repurchases ÷ mkt cap | +2.2% | +1.8% | 0.0% | +1.7% | +3.7% |
NGVT leads in 1 of 6 categories (Income & Cash Flow). CBT leads in 1 (Profitability & Efficiency). 4 tied.
NGVT vs FUL vs IOSP vs KWR vs CBT: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NGVT or FUL or IOSP or KWR or CBT a better buy right now?
For growth investors, Quaker Chemical Corporation (KWR) is the stronger pick with 2.
7% revenue growth year-over-year, versus -17. 0% for Ingevity Corporation (NGVT). Cabot Corporation (CBT) offers the better valuation at 14. 6x trailing P/E (13. 9x forward), making it the more compelling value choice. Analysts rate Ingevity Corporation (NGVT) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NGVT or FUL or IOSP or KWR or CBT?
On trailing P/E, Cabot Corporation (CBT) is the cheapest at 14.
6x versus H. B. Fuller Company at 23. 1x. On forward P/E, H. B. Fuller Company is actually cheaper at 13. 5x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Innospec Inc. wins at 0. 56x versus H. B. Fuller Company's 4. 34x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — NGVT or FUL or IOSP or KWR or CBT?
Over the past 5 years, Cabot Corporation (CBT) delivered a total return of +55.
8%, compared to -36. 1% for Quaker Chemical Corporation (KWR). Over 10 years, the gap is even starker: CBT returned +119. 6% versus FUL's +50. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NGVT or FUL or IOSP or KWR or CBT?
By beta (market sensitivity over 5 years), Innospec Inc.
(IOSP) is the lower-risk stock at 0. 70β versus Quaker Chemical Corporation's 1. 36β — meaning KWR is approximately 96% more volatile than IOSP relative to the S&P 500. On balance sheet safety, Innospec Inc. (IOSP) carries a lower debt/equity ratio of 7% versus 42% for Ingevity Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — NGVT or FUL or IOSP or KWR or CBT?
By revenue growth (latest reported year), Quaker Chemical Corporation (KWR) is pulling ahead at 2.
7% versus -17. 0% for Ingevity Corporation (NGVT). On earnings-per-share growth, the picture is similar: Innospec Inc. grew EPS 228. 9% year-over-year, compared to -102. 2% for Quaker Chemical Corporation. Over a 3-year CAGR, KWR leads at -1. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NGVT or FUL or IOSP or KWR or CBT?
Cabot Corporation (CBT) is the more profitable company, earning 8.
9% net margin versus -14. 3% for Ingevity Corporation — meaning it keeps 8. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NGVT leads at 22. 4% versus 8. 8% for IOSP. At the gross margin level — before operating expenses — NGVT leads at 39. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NGVT or FUL or IOSP or KWR or CBT more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Innospec Inc. (IOSP) is the more undervalued stock at a PEG of 0. 56x versus H. B. Fuller Company's 4. 34x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, H. B. Fuller Company (FUL) trades at 13. 5x forward P/E versus 20. 6x for Quaker Chemical Corporation — 7. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IOSP: 32. 8% to $115. 00.
08Which pays a better dividend — NGVT or FUL or IOSP or KWR or CBT?
In this comparison, CBT (2.
0% yield), IOSP (2. 0% yield), FUL (1. 4% yield), KWR (1. 4% yield) pay a dividend. NGVT does not pay a meaningful dividend and should not be held primarily for income.
09Is NGVT or FUL or IOSP or KWR or CBT better for a retirement portfolio?
For long-horizon retirement investors, Innospec Inc.
(IOSP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 70), 2. 0% yield, +105. 2% 10Y return). Both have compounded well over 10 years (IOSP: +105. 2%, NGVT: +111. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NGVT and FUL and IOSP and KWR and CBT?
Both stocks operate in the Basic Materials sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: NGVT is a small-cap quality compounder stock; FUL is a small-cap quality compounder stock; IOSP is a small-cap quality compounder stock; KWR is a small-cap quality compounder stock; CBT is a small-cap deep-value stock. FUL, IOSP, KWR, CBT pay a dividend while NGVT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.